Biomarin Pharmaceutical Stock Performance
| BMRN Stock | USD 64.26 0.81 1.28% |
The firm shows a Beta (market volatility) of 0.43, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biomarin Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biomarin Pharmaceutical is expected to be smaller as well. At this point, Biomarin Pharmaceutical has a negative expected return of -0.5%. Please make sure to confirm Biomarin Pharmaceutical's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Biomarin Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.31 | Five Day Return 5.05 | Year To Date Return (33.61) | Ten Year Return (27.22) | All Time Return 395.81 |
1 | Disposition of 372 shares by Erin Burkhart of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3 | 09/27/2024 |
2 | Why BioMarin Pharmaceutical is a Top Growth Stock for the Long-Term | 09/30/2024 |
3 | Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra and Altuviiio Intensify and Hympavzi Receives Approval, According to Spherix Gl... | 10/14/2024 |
4 | BioMarin Pharmaceutical Downgraded by William Blair | 10/30/2024 |
5 | BioMarin Upgraded to Buy Heres Why | 11/04/2024 |
6 | RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to... | 11/05/2024 |
7 | Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical | 11/07/2024 |
8 | Elliott Partner Bhanji Is Leaving Firm After More Than a Decade | 11/11/2024 |
9 | Sangamo Therapeutics SWOT analysis gene therapy firms stock faces challenges, opportunities | 11/13/2024 |
10 | Biomarin pharmaceuticals CTO sells 350k in stock | 11/14/2024 |
11 | BioMarin Pharmaceutical Inc. Among the Best Genomics Stocks to Buy Right Now | 11/19/2024 |
12 | Why Is BioMarin Pharmaceutical Inc. Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
13 | Can BioMarin Stock Live Up to Wall Streets High Expectations | 11/22/2024 |
| Begin Period Cash Flow | 724.5 M |
Biomarin |
Biomarin Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 9,046 in Biomarin Pharmaceutical on August 27, 2024 and sell it today you would lose (2,620) from holding Biomarin Pharmaceutical or give up 28.96% of portfolio value over 90 days. Biomarin Pharmaceutical is currently does not generate positive expected returns and assumes 2.5656% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Biomarin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biomarin Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomarin Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biomarin Pharmaceutical, and traders can use it to determine the average amount a Biomarin Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1938
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMRN |
Estimated Market Risk
| 2.57 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomarin Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomarin Pharmaceutical by adding Biomarin Pharmaceutical to a well-diversified portfolio.
Biomarin Pharmaceutical Fundamentals Growth
Biomarin Stock prices reflect investors' perceptions of the future prospects and financial health of Biomarin Pharmaceutical, and Biomarin Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomarin Stock performance.
| Return On Equity | 0.0625 | ||||
| Return On Asset | 0.03 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 11.92 B | ||||
| Shares Outstanding | 190.58 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 2.26 X | ||||
| Price To Sales | 4.45 X | ||||
| Revenue | 2.42 B | ||||
| Gross Profit | 1.61 B | ||||
| EBITDA | 310.28 M | ||||
| Net Income | 167.65 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 1.13 B | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 28.41 X | ||||
| Cash Flow From Operations | 159.26 M | ||||
| Earnings Per Share | 1.66 X | ||||
| Market Capitalization | 12.25 B | ||||
| Total Asset | 6.84 B | ||||
| Retained Earnings | (621.55 M) | ||||
| Working Capital | 1.78 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
About Biomarin Pharmaceutical Performance
By examining Biomarin Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Biomarin Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biomarin Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 784.93 | 449.28 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.03 | 0.04 | |
| Return On Assets | 0.02 | 0.03 | |
| Return On Equity | 0.03 | 0.04 |
Things to note about Biomarin Pharmaceutical performance evaluation
Checking the ongoing alerts about Biomarin Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biomarin Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biomarin Pharmaceutical generated a negative expected return over the last 90 days | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from marketbeat.com: Can BioMarin Stock Live Up to Wall Streets High Expectations |
- Analyzing Biomarin Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomarin Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Biomarin Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biomarin Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomarin Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biomarin Pharmaceutical's stock. These opinions can provide insight into Biomarin Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.